JACOBIO-B (01167) Subsidiary Enters Licensing Agreement with AstraZeneca to Develop and Commercialize Pan-KRAS Inhibitor JAB-23E73

Stock News12-21 20:01

JACOBIO-B (01167) announced that its non-wholly owned subsidiary, Beijing JACOBIO Pharmaceuticals, has entered into a licensing and collaboration agreement with AstraZeneca PLC (AZN) to develop and commercialize the pan-KRAS inhibitor JAB-23E73.

Under the terms of the agreement, AstraZeneca will receive an exclusive global license (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) to research, develop, register, manufacture, and commercialize JAB-23E73. AstraZeneca will bear all costs and activities related to further development and commercialization in its designated region.

For mainland China (excluding Hong Kong SAR, Macau SAR, and Taiwan), the licensed product will be jointly developed and commercialized by both parties under a governance framework outlined in the agreement.

Beijing JACOBIO is entitled to receive an upfront payment of $100 million from AstraZeneca and may be eligible for additional milestone payments of up to $1.915 billion upon achieving certain development, regulatory, and commercial milestones.

Furthermore, upon successful commercialization of the licensed product, Beijing JACOBIO will receive tiered royalties based on net sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158438782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-21 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158438782","market":"fut","top_or_hot":-1,"title":"JACOBIO-B (01167) Subsidiary Enters Licensing Agreement with AstraZeneca to Develop and Commercialize Pan-KRAS Inhibitor JAB-23E73","media":"Stock News","content":"<p>JACOBIO-B (01167) announced that its non-wholly owned subsidiary, Beijing JACOBIO Pharmaceuticals, has entered into a licensing and collaboration agreement with AstraZeneca PLC (AZN) to develop and commercialize the pan-KRAS inhibitor JAB-23E73.</p>\n<p>Under the terms of the agreement, AstraZeneca will receive an exclusive global license (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) to research, develop, register, manufacture, and commercialize JAB-23E73. AstraZeneca will bear all costs and activities related to further development and commercialization in its designated region.</p>\n<p>For mainland China (excluding Hong Kong SAR, Macau SAR, and Taiwan), the licensed product will be jointly developed and commercialized by both parties under a governance framework outlined in the agreement.</p>\n<p>Beijing JACOBIO is entitled to receive an upfront payment of $100 million from AstraZeneca and may be eligible for additional milestone payments of up to $1.915 billion upon achieving certain development, regulatory, and commercial milestones.</p>\n<p>Furthermore, upon successful commercialization of the licensed product, Beijing JACOBIO will receive tiered royalties based on net sales.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JACOBIO-B (01167) Subsidiary Enters Licensing Agreement with AstraZeneca to Develop and Commercialize Pan-KRAS Inhibitor JAB-23E73</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJACOBIO-B (01167) Subsidiary Enters Licensing Agreement with AstraZeneca to Develop and Commercialize Pan-KRAS Inhibitor JAB-23E73\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-21 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JACOBIO-B (01167) announced that its non-wholly owned subsidiary, Beijing JACOBIO Pharmaceuticals, has entered into a licensing and collaboration agreement with AstraZeneca PLC (AZN) to develop and commercialize the pan-KRAS inhibitor JAB-23E73.</p>\n<p>Under the terms of the agreement, AstraZeneca will receive an exclusive global license (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) to research, develop, register, manufacture, and commercialize JAB-23E73. AstraZeneca will bear all costs and activities related to further development and commercialization in its designated region.</p>\n<p>For mainland China (excluding Hong Kong SAR, Macau SAR, and Taiwan), the licensed product will be jointly developed and commercialized by both parties under a governance framework outlined in the agreement.</p>\n<p>Beijing JACOBIO is entitled to receive an upfront payment of $100 million from AstraZeneca and may be eligible for additional milestone payments of up to $1.915 billion upon achieving certain development, regulatory, and commercial milestones.</p>\n<p>Furthermore, upon successful commercialization of the licensed product, Beijing JACOBIO will receive tiered royalties based on net sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1158438782","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158438782","pubTimestamp":1766318472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JACOBIO-B (01167) announced that its non-wholly owned subsidiary, Beijing JACOBIO Pharmaceuticals, has entered into a licensing and collaboration agreement with AstraZeneca PLC (AZN) to develop and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","BK1161":"生物科技","BK4585":"ETF&股票定投概念","AZN":"阿斯利康","BK4007":"制药","BK1574":"生物医药B类股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","01167":"加科思-B","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC"},"translate_title":"雅可比-B(01167)附属公司与阿斯利康订立许可协议开发及商业化泛KRAS抑制剂JAB-23E73","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"01167":1},"content_text":"JACOBIO-B (01167) announced that its non-wholly owned subsidiary, Beijing JACOBIO Pharmaceuticals, has entered into a licensing and collaboration agreement with AstraZeneca PLC (AZN) to develop and commercialize the pan-KRAS inhibitor JAB-23E73.\nUnder the terms of the agreement, AstraZeneca will receive an exclusive global license (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) to research, develop, register, manufacture, and commercialize JAB-23E73. AstraZeneca will bear all costs and activities related to further development and commercialization in its designated region.\nFor mainland China (excluding Hong Kong SAR, Macau SAR, and Taiwan), the licensed product will be jointly developed and commercialized by both parties under a governance framework outlined in the agreement.\nBeijing JACOBIO is entitled to receive an upfront payment of $100 million from AstraZeneca and may be eligible for additional milestone payments of up to $1.915 billion upon achieving certain development, regulatory, and commercial milestones.\nFurthermore, upon successful commercialization of the licensed product, Beijing JACOBIO will receive tiered royalties based on net sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158438782","isCrawlerRequest":true}